Trials / Terminated
TerminatedNCT02104336
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Edison Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Treatment of Pediatric Subjects with Pearson syndrome
Detailed description
If effective, treatment with EPI-743 should result in a significant reduction in occurrence of sepsis, metabolic crisis, hepatic failure and transfusion dependence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPI-743 | EPI-743 is the quinone oxidation product of alpha-tocotrienol |
Timeline
- Start date
- 2014-08-31
- Primary completion
- 2015-11-30
- Completion
- 2016-02-29
- First posted
- 2014-04-04
- Last updated
- 2020-11-18
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02104336. Inclusion in this directory is not an endorsement.